ReviewJournal of immunology research2016
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
Review in Journal of immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.Journal of cancer research and clinical oncology · 2023Article
- CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.Clinical and experimental medicine · 2023Article
- Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.Experimental hematology & oncology · 2022Review
- NK cell upraise in the dark world of cancer stem cells.Cancer cell international · 2021Review
- Born to survive: how cancer cells resist CAR T cell therapy.Journal of hematology & oncology · 2021Review
- Review
- Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases.Cancers · 2021Article
- CAR-NK Cells: From Natural Basis to Design for Kill.Frontiers in immunology · 2021Review
- Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.Frontiers in immunology · 2021Review
- Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.Journal of hematology & oncology · 2020Review
- GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.International journal of cancer · 2020Article
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.Journal of hematology & oncology · 2019Article
- Cancer biomarkers for targeted therapy.Biomarker research · 2019Article
- Chimeric antigen receptor modified T-cells for cancer treatment.Chronic diseases and translational medicine · 2018Article
- Rhein enhances the cytotoxicity of effector lymphocytes in colon cancer under hypoxic conditions.Experimental and therapeutic medicine · 2018Article
- Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.Cancer immunology, immunotherapy : CII · 2018Review
- Polyclonal Rabbit Anti-Cancer-Associated Fibroblasts Globulins Induce Cancer Cells Apoptosis and Inhibit Tumor Growth.International journal of biological sciences · 2018Article
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Medicinal research reviews · 2018Review
- Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.BioMed research international · 2018Review
- Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.Human vaccines & immunotherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. The few published clinical studies of CART cells in solid tumors have addressed safety and feasibility, but the clinical outcome data are limited. Although antitumor effects were confirmed in vitro and in animal models, CART-cell-based therapy still faces several challenges when directed towards solid tumors, and it has been difficult to achieve the desired outcomes in clinical practice. Many studies have struggled to improve the clinical responses to and benefits of CART-cell treatment of solid tumors. In this review, the status quo of CART cells and their clinical applications for solid tumors will be summarized first. Importantly, we will suggest improvements that could increase the therapeutic effectiveness of CART cells for solid tumors and their future clinical applications. These interventions will make treatment with CART cells an effective and routine therapy for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.